Motus GI's latest twelve months ebitda is zero Motus GI's ebitda hit its 5-year low in December 2020 of -18.67 million. Motus GI's ebitda increased in 2020 (-18.67 million, -19.4%), 2021 (-17.485 ...

Successfully ramped up limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of ...

Motus GI Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update. Successfully ramped up limited U.S. commercial launch of the Pure-Vu ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (MOTS), (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and ...

Initiated limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systems The Company is engaged in the ...

Mr. Aldrich has years of interventional gastroenterology and medical device imaging experience, and is expected to help EndoSound capitalize on its EndoSound EVS technology, which converts any ...

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and ...

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, ...